Biodistribution and Dosimetry Evaluation of the Radiolabeled Somatostatin Receptor Antagonist 68 Ga-DATA 5m LM4 in Molecular Imaging of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors Patients.

IF 9.6 3区医学 Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Clinical Nuclear Medicine Pub Date : 2025-04-01 Epub Date: 2025-01-06 DOI:10.1097/RLU.0000000000005649

Sanjana Ballal, Parvind Sheokand, Madhav P Yadav, Frank Roesch, Rahul Viswanathan, Swayamjeet Satapathy, Madhavi Tripathi, Euy Sung Moon, Prashant Mishra, Sameer Rastogi, Shipra Agarwal, Chandrasekhar Bal

{"title":"Biodistribution and Dosimetry Evaluation of the Radiolabeled Somatostatin Receptor Antagonist 68 Ga-DATA 5m LM4 in Molecular Imaging of Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors Patients.","authors":"Sanjana Ballal, Parvind Sheokand, Madhav P Yadav, Frank Roesch, Rahul Viswanathan, Swayamjeet Satapathy, Madhavi Tripathi, Euy Sung Moon, Prashant Mishra, Sameer Rastogi, Shipra Agarwal, Chandrasekhar Bal","doi":"10.1097/RLU.0000000000005649","DOIUrl":null,"url":null,"abstract":"Purpose: This study aimed to assess the biodistribution and radiation dosimetry of 68 Ga-DATA 5m LM4 in patients with gastroenteropancreatic neuroendocrine tumors.Patients and methods: Eight patients (5 females and 3 males) with various gastroenteropancreatic neuroendocrine tumors were included in the study. Each patient underwent 3 whole-body PET scans at 10, 60, and 120 minutes after receiving an IV injection of approximately 162.5 MBq of 68 Ga-DATA 5m LM4. Organs considered for dosimetric analysis included the liver, heart, spleen, kidneys, adrenal glands, and lumbar vertebrae (L2 to L4). Dosimetric calculations were performed using the OLINDA/EXM 2.2 software.Results: Physiological uptake of 68 Ga-DATA 5m LM4 was observed in the pituitary gland, spleen, liver, adrenal glands, and the urinary tract (kidneys and urinary bladder) for all patients. The kidneys received the highest absorbed doses at (4.77E-02 ± 1.49E-02 mSv/MBq). The mean effective dose was 2.61E-03 ± 5.99E-04 mSv/MBq.Conclusions: 68 Ga-DATA 5m LM4 injection is safe and is primarily excreted through urine, delivering the highest radiation dose to the kidneys.","PeriodicalId":10692,"journal":{"name":"Clinical Nuclear Medicine","volume":"50 4","pages":"e194-e201"},"PeriodicalIF":9.6000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/RLU.0000000000005649","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/6 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study aimed to assess the biodistribution and radiation dosimetry of 68 Ga-DATA 5m LM4 in patients with gastroenteropancreatic neuroendocrine tumors.

Patients and methods: Eight patients (5 females and 3 males) with various gastroenteropancreatic neuroendocrine tumors were included in the study. Each patient underwent 3 whole-body PET scans at 10, 60, and 120 minutes after receiving an IV injection of approximately 162.5 MBq of 68 Ga-DATA 5m LM4. Organs considered for dosimetric analysis included the liver, heart, spleen, kidneys, adrenal glands, and lumbar vertebrae (L2 to L4). Dosimetric calculations were performed using the OLINDA/EXM 2.2 software.

Results: Physiological uptake of 68 Ga-DATA 5m LM4 was observed in the pituitary gland, spleen, liver, adrenal glands, and the urinary tract (kidneys and urinary bladder) for all patients. The kidneys received the highest absorbed doses at (4.77E-02 ± 1.49E-02 mSv/MBq). The mean effective dose was 2.61E-03 ± 5.99E-04 mSv/MBq.

Conclusions: 68 Ga-DATA 5m LM4 injection is safe and is primarily excreted through urine, delivering the highest radiation dose to the kidneys.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Nuclear Medicine 医学-核医学

CiteScore

2.90

自引率

31.10%

发文量

1113

审稿时长

2 months

期刊介绍： Clinical Nuclear Medicine is a comprehensive and current resource for professionals in the field of nuclear medicine. It caters to both generalists and specialists, offering valuable insights on how to effectively apply nuclear medicine techniques in various clinical scenarios. With a focus on timely dissemination of information, this journal covers the latest developments that impact all aspects of the specialty. Geared towards practitioners, Clinical Nuclear Medicine is the ultimate practice-oriented publication in the field of nuclear imaging. Its informative articles are complemented by numerous illustrations that demonstrate how physicians can seamlessly integrate the knowledge gained into their everyday practice.